Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G

This randomized phase II trial compared panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) with bevacizumab plus FOLFIRI as second‐line chemotherapy for wild‐type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and to explore the values of oncogenes in circulating tumor DNA (ct...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Sci
Main Authors: Shitara, Kohei, Yonesaka, Kimio, Denda, Tadamichi, Yamazaki, Kentaro, Moriwaki, Toshikazu, Tsuda, Masahiro, Takano, Toshimi, Okuda, Hiroyuki, Nishina, Tomohiro, Sakai, Kazuko, Nishio, Kazuto, Tokunaga, Shoji, Yamanaka, Takeharu, Boku, Narikazu, Hyodo, Ichinosuke, Muro, Kei
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2016
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5198953/
https://ncbi.nlm.nih.gov/pubmed/27712015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13098
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares